BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 28159923)

  • 1. The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
    Craveiro RB; Ehrhardt M; Velz J; Olschewski M; Goetz B; Pietsch T; Dilloo D
    Oncotarget; 2017 Jul; 8(29):46915-46927. PubMed ID: 28159923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.
    Ehrhardt M; Craveiro RB; Velz J; Olschewski M; Casati A; Schönberger S; Pietsch T; Dilloo D
    J Cell Mol Med; 2018 Apr; 22(4):2153-2161. PubMed ID: 29377550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
    Ehrhardt M; Craveiro RB; Holst MI; Pietsch T; Dilloo D
    Oncotarget; 2015 Jan; 6(2):802-13. PubMed ID: 25596739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.
    Craveiro RB; Ehrhardt M; Holst MI; Pietsch T; Dilloo D
    Oncotarget; 2014 Aug; 5(16):7149-61. PubMed ID: 25216529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
    Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
    Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.
    Kumar A; Fillmore HL; Kadian R; Broaddus WC; Tye GW; Van Meter TE
    Mol Cancer Res; 2009 Nov; 7(11):1813-21. PubMed ID: 19887560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of STAT3 NH
    Ray S; Coulter DW; Gray SD; Sughroue JA; Roychoudhury S; McIntyre EM; Chaturvedi NK; Bhakat KK; Joshi SS; McGuire TR; Sharp JG
    Mol Carcinog; 2018 Apr; 57(4):536-548. PubMed ID: 29280516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
    Heavey S; Cuffe S; Finn S; Young V; Ryan R; Nicholson S; Leonard N; McVeigh N; Barr M; O'Byrne K; Gately K
    Oncotarget; 2016 Nov; 7(48):79526-79543. PubMed ID: 27765909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
    Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
    Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor.
    Wang S; Zhang D; Wang J; Peng X; Sun H; Ji Y; Yang Z; Bian X; Hou Y; Ge M; Liu Y
    J Neurooncol; 2024 May; 168(1):139-149. PubMed ID: 38662151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
    Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.
    Macy ME; DeRyckere D; Gore L
    Invest New Drugs; 2012 Apr; 30(2):468-79. PubMed ID: 21046425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
    Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
    Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.
    Yang F; Jove V; Chang S; Hedvat M; Liu L; Buettner R; Tian Y; Scuto A; Wen W; Yip ML; Van Meter T; Yen Y; Jove R
    Cancer Biol Ther; 2012 Apr; 13(6):349-57. PubMed ID: 22313636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
    Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
    PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
    Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
    Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
    Chaturvedi NK; Mahapatra S; Kesherwani V; Kling MJ; Shukla M; Ray S; Kanchan R; Perumal N; McGuire TR; Sharp JG; Joshi SS; Coulter DW
    BMC Cancer; 2019 Nov; 19(1):1056. PubMed ID: 31694585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.
    Gottlieb A; Althoff K; Grunewald L; Thor T; Odersky A; Schulte M; Deubzer HE; Heukamp L; Eggert A; Schramm A; Schulte JH; Künkele A
    Oncotarget; 2017 Apr; 8(17):27882-27891. PubMed ID: 28427187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells.
    Elamin MH; Shinwari Z; Hendrayani SF; Al-Hindi H; Al-Shail E; Khafaga Y; Al-Kofide A; Aboussekhra A
    Mol Carcinog; 2010 Mar; 49(3):302-14. PubMed ID: 20025076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triptolide inhibits the proliferation and migration of medulloblastoma Daoy cells by upregulation of microRNA-138.
    Zhang H; Li H; Liu Z; Ge A; Guo E; Liu S; Chen Z
    J Cell Biochem; 2018 Dec; 119(12):9866-9877. PubMed ID: 30156009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.